Inhibrx Biosciences Inc.
Price
Overview
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Inhibrx Biosciences Inc., its business model, key products, and controversies.